Teacher Retirement System of Texas cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 587,937 shares of the biopharmaceutical company’s stock after selling 35,218 shares during the quarter. Teacher Retirement System of Texas’ holdings in Gilead Sciences were worth $39,721,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Dimensional Fund Advisors LP increased its holdings in shares of Gilead Sciences by 1.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock valued at $320,822,000 after purchasing an additional 51,905 shares during the period. Peoples Financial Services CORP. increased its holdings in shares of Gilead Sciences by 48.2% in the first quarter. Peoples Financial Services CORP. now owns 2,153 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 700 shares during the period. Highland Capital Management LLC increased its holdings in shares of Gilead Sciences by 0.6% in the first quarter. Highland Capital Management LLC now owns 35,513 shares of the biopharmaceutical company’s stock valued at $2,309,000 after purchasing an additional 196 shares during the period. Asset Dedication LLC increased its holdings in shares of Gilead Sciences by 5.8% in the first quarter. Asset Dedication LLC now owns 6,837 shares of the biopharmaceutical company’s stock valued at $440,000 after purchasing an additional 373 shares during the period. Finally, Plimoth Trust Co. LLC increased its holdings in shares of Gilead Sciences by 0.6% in the first quarter. Plimoth Trust Co. LLC now owns 44,776 shares of the biopharmaceutical company’s stock valued at $2,911,000 after purchasing an additional 245 shares during the period. Institutional investors own 78.78% of the company’s stock.

A number of research analysts have recently issued reports on GILD shares. Raymond James boosted their target price on Gilead Sciences from $83.00 to $86.00 and gave the company a “strong-buy” rating in a report on Wednesday, July 31st. Morgan Stanley set a $82.00 target price on Gilead Sciences and gave the company a “hold” rating in a report on Monday, July 15th. BMO Capital Markets set a $82.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, July 31st. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $85.00 price objective on shares of Gilead Sciences in a report on Wednesday, July 31st. Finally, Oppenheimer set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, July 12th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $82.29.

In related news, EVP Brett A. Pletcher sold 7,200 shares of the company’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total value of $468,504.00. Following the completion of the transaction, the executive vice president now directly owns 34,398 shares in the company, valued at $2,238,277.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 608 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The disclosure for this sale can be found here. Insiders sold 13,624 shares of company stock worth $907,479 over the last 90 days. Company insiders own 0.20% of the company’s stock.

GILD traded up $0.52 during trading on Wednesday, reaching $63.96. 2,570,643 shares of the stock were exchanged, compared to its average volume of 6,233,067. The business’s 50 day moving average price is $65.84 and its two-hundred day moving average price is $65.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67. The company has a market capitalization of $81.13 billion, a price-to-earnings ratio of 10.40, a P/E/G ratio of 3.00 and a beta of 1.16. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. During the same period in the prior year, the business earned $1.91 earnings per share. The business’s revenue was down 2.8% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post 6.65 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, September 12th. This represents a $2.52 annualized dividend and a dividend yield of 3.94%. Gilead Sciences’s dividend payout ratio is currently 40.98%.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What is a Stop Order?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.